Scinai Immunotherapeutics Ltd. Showcases Strategic Milestones and Funding Ahead of BIO 2025
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) prepares for the BIO International Convention 2025, highlighting its CDMO business growth and nanobody pipeline progress, alongside securing $1.38 million in funding to support its operations without additional dilution.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is set to make a significant appearance at the BIO International Convention 2025 in Boston, where CEO Amir Reichman will present the company's recent achievements. These include notable growth in its Contract Development and Manufacturing Organization (CDMO) business and advancements in its nanobody pipeline. The company's participation underscores its commitment to innovation in the biopharmaceutical sector, particularly in inflammation and immunology treatments.
In a strategic financial move, Scinai has secured $1.38 million through a Standby Equity Purchase Agreement with Yorkville Advisors. This funding is pivotal as it enhances the company's capital without the need for warrants or causing additional dilution to existing shareholders. Such financial prudence is crucial for sustaining operations and fueling growth in a competitive industry.
Scinai has also reaffirmed its 2025 CDMO revenue guidance at $2 million, with the ambition to reach breakeven by 2026. These targets reflect the company's confidence in its business model and its ability to capitalize on the growing demand for biopharmaceutical development and manufacturing services. The announcement is significant for investors and the biotech industry, as it highlights Scinai's progress towards financial sustainability and its potential to contribute to addressing unmet medical needs through its innovative NanoAbs technology.